The estimated Net Worth of Gotham Makker is at least $17.5 Milion dollars as of 21 March 2024. Gotham Makker owns over 274,000 units of Rocket Pharmaceuticals Inc stock worth over $6,963,305 and over the last 7 years he sold RCKT stock worth over $10,199,970. In addition, he makes $325,912 as Independent Director at Rocket Pharmaceuticals Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Gotham Makker RCKT stock SEC Form 4 insiders trading
Gotham has made over 4 trades of the Rocket Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 274,000 units of RCKT stock worth $7,789,820 on 21 March 2024.
The largest trade he's ever made was selling 274,000 units of Rocket Pharmaceuticals Inc stock on 21 March 2024 worth over $7,789,820. On average, Gotham trades about 28,673 units every 84 days since 2018. As of 21 March 2024 he still owns at least 365,912 units of Rocket Pharmaceuticals Inc stock.
You can see the complete history of Gotham Makker stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Gotham Makker biography
Dr. Gotham Makker M.D. serves as Independent Director of the Company. Dr. Makker has over 17 years of healthcare industry experience. Dr. Makker currently serves as head of Strategic Investments for RTW Investments, LP (“RTW”), a position he has held since 2019. From 2005 to 2019, he served as Chief Executive Officer of Simran Investment Group, LLC, a closely held equity investment fund. Prior to Simran, Dr. Makker was a healthcare portfolio manager and principal at Citadel Investment Group LLC, a position he held from 2002 to 2005. Prior to joining Citadel, Dr. Makker served as an analyst at Oracle Partners LP covering biotechnology and medical device sectors from 2000 to 2001. From 1999 to 2000, Dr. Makker was a senior analyst on the life sciences investment banking team at Hambrecht & Quist. Dr. Makker has previously served on the board of directors of Health Sciences Acquisitions Corporation. Dr. Makker received an M.D. from the University of Nebraska Medical School, and he completed the Sarnoff cardiovascular research fellowship at Columbia University, College of Physicians & Surgeons and at Harvard Medical School, Brigham & Women’s Hospital.
What is the salary of Gotham Makker?
As the Independent Director of Rocket Pharmaceuticals Inc, the total compensation of Gotham Makker at Rocket Pharmaceuticals Inc is $325,912. There are 12 executives at Rocket Pharmaceuticals Inc getting paid more, with Gaurav Shah having the highest compensation of $3,883,650.
How old is Gotham Makker?
Gotham Makker is 45, he's been the Independent Director of Rocket Pharmaceuticals Inc since 2018. There are 10 older and 6 younger executives at Rocket Pharmaceuticals Inc. The oldest executive at Rocket Pharmaceuticals Inc is Pedro Granadillo, 73, who is the Independent Director.
What's Gotham Makker's mailing address?
Gotham's mailing address filed with the SEC is C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY, NJ, 08512.
Insiders trading at Rocket Pharmaceuticals Inc
Over the last 7 years, insiders at Rocket Pharmaceuticals Inc have traded over $45,364,690 worth of Rocket Pharmaceuticals Inc stock and bought 2,407,332 units worth $48,979,646 . The most active insiders traders include Investments, Lpwong Roderic..., Mikael Dolsten oraz Investments, Lpwong Roderic.... On average, Rocket Pharmaceuticals Inc executives and independent directors trade stock every 30 days with the average trade being worth of $1,269,815. The most recent stock trade was executed by John Militello on 16 August 2024, trading 1,064 units of RCKT stock currently worth $19,684.
What does Rocket Pharmaceuticals Inc do?
rocket pharmaceuticals, ltd is a biotechnology company focused on seeking cures through molecular and gene therapy. we are developing first-in-class treatments for patients with rare and often devastating orphan diseases using a lentiviral-based gene therapy approach. we have developed rewarding partnerships with a number of leading international research institutions as well as with centers of manufacturing and cell processing expertise, while building an internal team to drive the research, development, clinical and regulatory programs. ultimately we aim to launch and globally commercialize innovative gene therapies in disease areas with high unmet need. for more information, please visit www.rocketpharma.com.
What does Rocket Pharmaceuticals Inc's logo look like?
Complete history of Gotham Makker stock trades at Rocket Pharmaceuticals Inc
Rocket Pharmaceuticals Inc executives and stock owners
Rocket Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Gaurav Shah,
President, Chief Executive Officer, Director -
Kinnari Patel,
Chief Operating Officer and Head of Development -
Kamran Alam,
Senior Vice President - Finance, Principal Financial Officer -
Jonathan Schwartz,
Chief Medical Officer -
Dr. Gaurav D. Shah,
CEO & Director -
Kinnari Patel M.B.A., Pharm.D., PharmD, MBA,
Pres, COO & Head of Devel. -
Jonathan Schwartz,
Chief Medical Officer & Sr. VP of Clinical Devel. -
John C. Militello CPA, CPA,
VP, Sr. Controller & Principal Accounting Officer -
Roderick Wong,
Chairman of the Board -
Pedro Granadillo,
Independent Director -
Carsten Boess,
Independent Director -
Naveen Yalamanchi,
Independent Director -
Gotham Makker,
Independent Director -
David Southwell,
Director -
Elisabeth Bjork,
Independent Director -
John Militello,
Principal Accounting Officer and Senior Controller -
Dr. Gayatri R. Rao J.D., M.D.,
Chief Devel. Officer of LVV & Sr. VP -
Isabel Carmona J.D.,
Sr. VP & Chief HR Officer -
Kevin Giordano,
Director of Corp. Communications -
Martin L. Wilson,
Gen. Counsel, Chief Compliance Officer & Sr. VP -
Mayur Kasetty,
Bus. Devel. & Operations and Investor Relations Lead -
Carlos Garcia-Parada M.B.A.,
Chief Financial Officer -
Investments, Lpwong Roderic...,
-
Mark Andrew White,
See Remarks -
Investments, Lpwong Roderic...,
-
Roderickrtw Investments, Lp...,
-
Keith Woods,
-
Fady Ibraham Malik,
-
Carlos Garcia Parada,
Chief Financial Officer -
Martin Wilson,
General Counsel -
Mikael Dolsten,
-
Aaron Ondrey,
Chief Financial Officer